Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Prof. Joseph Zohar, Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00229385
First received: September 28, 2005
Last updated: December 30, 2013
Last verified: December 2013
  Purpose
Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

Condition Intervention
Schizophrenia
Obsessive Compulsive Disorder
Drug: Ziprasidone

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • YBOCS [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 45
Study Start Date: January 2006
Study Completion Date: April 2010
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Ziprasidone
40-80 mg BID
Active Comparator: 2 Drug: Ziprasidone
40-80 mg BID

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Schizophrenia and OCD for at least 6 months
  • Minimum score of 14 on YBOCS
  • Minimum score of 60 on PANSS
  • Diagnosis of Schizophrenia without OC symptoms

Exclusion Criteria:

  • Patients who are already being treated with ziprasidone
  • Diagnosis of schizophreniform disorder
  • Organic brain syndrome, mental retardation and pervasive developmental disorder
  • Patients having any significantly cardiovascular illness or electrolyte imbalance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00229385

Locations
Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Joseph Zohar, MD Tel Aviv University
  More Information

Responsible Party: Prof. Joseph Zohar, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00229385     History of Changes
Other Study ID Numbers: SHEBA-03-3061-JS-CTIL 
Study First Received: September 28, 2005
Last Updated: December 30, 2013
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Disease
Schizophrenia
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Compulsive Behavior
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Personality Disorders
Anxiety Disorders
Impulsive Behavior
Ziprasidone
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents

ClinicalTrials.gov processed this record on December 06, 2016